Impact of molecular testing in advanced melanoma on outcomes in a tertiary cancer center and as reported in a publicly available database.

Public datasets provide population-level data; however, the heterogeneity of reported clinical information limits their value and calls for data standardization. Without evidence of clear clinical benefit of a larger panel size, there is a rationale for adopting smaller, more cost effective panels in MM.